子宫内膜癌循环microRNA的电化学生物传感检测
综述评估循环microRNA作为子宫内膜癌微创标志物的价值,及电化学生物传感平台在检验医学中的应用。文章分析其低浓度、序列同源性、isomiR干扰和预分析变异等挑战,并讨论标准化校准、临床基质验证及与qPCR/dPCR比对等转化障碍。
要点
- 循环microRNA有潜力用于子宫内膜癌早期检测、风险分层、疗效监测和复发评估。
- 电化学生物传感具直接信号转导、低样本量、高通量和可自动化等优势。
- 临床转化需解决标准化校准、血浆/血清验证及与参考方法比对等问题。
核心结论
- 电化学生物传感检测循环microRNA在子宫内膜癌实验室医学中具应用前景,但临床转化仍受标准化和验证不足限制。
研究设计与样本
- 综述,评估循环microRNA特征及电化学生物传感平台在检验医学中的验证、质量保证和监管流程。
主要发现
- 循环microRNA低浓度、miRNA家族成员高度序列同源、isomiR干扰和预分析变异影响重现性和实验室间可比性。
- 电极纳米结构化、探针工程和微流控整合提升了分析灵敏度和多重检测能力。
- 缺乏标准化校准和归一化方案、血浆/血清等临床基质验证不足、与qPCR和dPCR等参考方法缺乏完整比对是转化障碍。
临床怎么用
- 临床方法应用取决于其在实际基质中的重现性、对参考方法的溯源性和 accreditation。
局限性
- 缺乏标准化校准和归一化协议,临床相关基质验证不充分,与qPCR和dPCR等参考方法缺乏完整比对。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The global incidence of endometrial cancer (EC) is increasing; however, current diagnostic and surveillance methodologies, which rely on invasive sampling and imaging, are insufficient for detecting early molecular alterations and accurately predicting treatment resistance and recurrence. Circulating microRNAs (c-miRNAs) are promising minimally invasive biomarkers that reflect tumor biology and disease dynamics. Nevertheless, their application in laboratory medicine is limited due to their low concentrations in circulation, the high degree of sequence homology among miRNA family members, interference from isomiRs, and preanalytical variability, all of which compromise reproducibility and inter-laboratory comparability. Electrochemical biosensing is an emerging analysis platform in clinical chemistry because of its ability to directly transduce signal changes as a result of hybridization, high turnaround, capability to operate using low sample volumes, and compatibility with automated and decentralized workflows. The nanostructuring of electrodes, engineering of probes, and integration of microfluidic systems have significantly enhanced the sensitivity of analytical processes and improved multiplexing capabilities. However, some of the critical barriers to translation, such as the absence of standardized calibration and normalization protocols, inadequate validation in clinically relevant matrices (plasma/serum) and a complete comparison of methods with established reference procedures, such as quantitative PCR and digital PCR, are still present. This review critically evaluates c-miRNA signatures and electrochemical biosensing platforms in laboratory medicine, examining validation, quality assurance, and regulatory processes for clinically actionable assays supporting early detection, risk stratification, therapy monitoring, and recurrence assessment. The future use of clinical methods will hinge on their reproducibility in actual matrices, their traceability to reference methods, and their accreditation.
引用
- Patel N, Afzal M, Mishra R, et al. Electrochemical biosensing of circulating MicroRNAs in endometrial Cancer. Clin Chim Acta. 2026. PMID: 41956145. doi:10.1016/j.cca.2026.121002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。